Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2269)	12/10/2000 3:38:04 PM
From: Biomaven	of 52153

And here's an interesting biotech-relevant story that's been fulminating for a week or two: Biocentury's Cover Story: Patent Protection Narrows -- A U.S. appeals court decision promises to dramatically limit the ability of companies to protect their patents using the doctrine of equivalents, with several attorneys and at least two justices on the appeals panel cautioning that the ruling could severely limit the scope of protection for certain biotech patents. From biocentury.com (Full story available only to subscribers). The actual en banc decision is available at: ll.georgetown.edu Conceivably this might still go to the US Supreme Court if they don't get too distracted by other events which shall remain nameless here. <g> It's very hard to judge the full impact of this decision. Clearly it's a narrowing of rights for many patent holders, but to what extent remains to be seen. Partly it depends on the history of their patent application and the extent to which it was narrowed in the course of its prosecution. It may effect the AMGN/TKTX case some. I shorted a little AMGN and bought a little TKTX last week in case this new ruling is blown up out of proportion and has an impact on them. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next